

104201

5



10

15

17

20

R_z is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;

25

a) independently hydrogen,

10042203-01102

a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen, or

5 -OSi(R_f)₃ where R_f is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or

10 b) R_a and R_b together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O substituted by halogen, hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or

15 c) one of R_a or R_b is -C(O)-, a C₁-C₅ divalent alkylene group or a substituted C₁-C₅ divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C₁-C₅ divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected
20 from N, S and O and are optionally substituted by halogen;

where B is substituted, L is substituted or L¹ is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and W_n, where n is 0-3;

25 wherein each W is independently selected from the group consisting of -CN, -CO₂R⁷, -C(O)NR⁷R⁷, -C(O)-R⁷, -NO₂, -OR⁷, -SR⁷, -NR⁷R⁷, -NR⁷C(O)OR⁷, -NR⁷C(O)R⁷, -Q-Ar, and carbon based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents independently selected from the group consisting of -CN, -CO₂R⁷, -C(O)R⁷, -C(O)NR⁷R⁷, -OR⁷, -SR⁷, -NR⁷R⁷, -NO₂, -NR⁷C(O)R⁷, -NR⁷C(O)OR⁷ and

halogen up to per-halo; with each R^7 independently selected from H or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen,

wherein Q is -O-, -S-, -N(R^7)-, -(CH₂)_m-, -C(O)-, -CH(OH)-, -(CH₂)_mO-, -
5 (CH₂)_mS-, -(CH₂)_mN(R^7)-, -O(CH₂)_m-, CHX^a-, -CX^a₂-, -S-(CH₂)_m- and -N(R^7)(CH₂)_m-,
where m= 1-3, and X^a is halogen; and

Ar is a 5- or 6-member aromatic structure containing 0-2 members selected from the group consisting of nitrogen, oxygen and sulfur, which is optionally substituted by halogen, up to per-halo, and optionally substituted by Z_{n1}, wherein n1 is 0 to 3 and each Z
10 is independently selected from the group consisting of -CN, -CO₂R⁷, -C(O)R⁷, -C(O)NR⁷R⁷, -NO₂, -OR⁷, -SR⁷, -NR⁷R⁷, -NR⁷C(O)OR⁷, -NR⁷C(O)R⁷, and a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents selected from the group consisting of -CN, -CO₂R⁷, -COR⁷, -C(O)NR⁷R⁷, -OR⁷, -SR⁷, -NO₂, -NR⁷R⁷,
15 -NR⁷C(O)R⁷, and -NR⁷C(O)OR⁷, with R⁷ as defined above.

2. A compound as in claim 1 wherein:

R_y is hydrogen, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, C₃₋₁₀ cycloalkyl having 0-3 heteroatoms, C₂₋₁₀ alkenyl, C₁₋₁₀ alkenoyl, C₆₋₁₂ aryl, C₃₋₁₂ hetaryl having 1-3 heteroatoms selected
20 from N, S and O, C₇₋₂₄ aralkyl, C₇₋₂₄ alkaryl, substituted C₁₋₁₀ alkyl, substituted C₁₋₁₀ alkoxy, substituted C₃₋₁₀ cycloalkyl having 0-3 heteroatoms selected from N, S and O, substituted C₆-C₁₄ aryl, substituted C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from N, S and O, substituted C₇₋₂₄ alkaryl or substituted C₇-C₂₄ aralkyl, where R_y is a substituted group, it is substituted by halogen up to per halo,

25

R_z is hydrogen, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, C₃₋₁₀ cycloalkyl having 0-3 heteroatom, C₂₋₁₀ alkenyl, C₁₋₁₀ alkenoyl, C₆₋₁₂ aryl, C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from, S, N and O, C₇₋₂₄ alkaryl, C₇₋₂₄ aralkyl, substituted C₁₋₁₀ alkyl, substituted C₁₋₁₀ alkoxy, substituted C₆-C₁₄ aryl, substituted C₃-C₁₀ cycloalkyl having 0-3 heteroatoms

10042203 "011102

selected from S, N and O, substituted C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from S, N and O, substituted C₇₋₂₄ alkaryl or substituted C_{7-C24} aralkyl where R_z is a substituted group, it is substituted by halogen up to per halo, hydroxy, C₁₋₁₀ alkyl, C₃₋₁₂ cycloalkyl having 0-3 heteroatoms selected from O, S and N, C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from N, S and O, C₁₋₁₀ alkoxy, C₆₋₁₂ aryl, C₁₋₆ halo substituted alkyl up to per halo alkyl, C_{6-C12} halo substituted aryl up to per halo aryl, C_{3-C12} halo substituted cycloalkyl up to per halo cycloalkyl having 0-3 heteroatoms selected from N, S and O, halo substituted C_{3-C12} hetaryl up to per halo hetaryl having 1-3 heteroatoms selected from O, N and S, halo substituted C_{7-C24} aralkyl up to per halo aralkyl, halo substituted C_{7-C24} alkaryl up to per halo alkaryl, and -C(O)R_g,

R_a and R_b are,

a) independently hydrogen,
a carbon based moiety selected from the group consisting of C₁ -C₁₀ alkyl, C₁ -C₁₀ alkoxy, C₃₋₁₀ cycloalkyl, C₂₋₁₀ alkenyl, C₁₋₁₀ alkenoyl, C₆₋₁₂ aryl, C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from O, N and S, C₃₋₁₂ cycloalkyl having 0-3 heteroatoms selected from N, S and O, C₇₋₂₄ aralkyl, C_{7-C24} alkaryl, substituted C₁₋₁₀ alkyl, substituted C₁₋₁₀ alkoxy, substituted C₃₋₁₀ cycloalkyl, having 0-3 heteroatoms selected from N, S and O, substituted C₆₋₁₂ aryl, substituted C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from N, S and O, substituted C₇₋₂₄ aralkyl, substituted C₇₋₂₄ alkaryl, where R_a and R_b are a substituted group, they are substituted by halogen up to per halo, hydroxy, C₁₋₁₀ alkyl, C₃₋₁₂ cycloalkyl having 0-3 heteroatoms selected from O, S and N, C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from N, S and O, C₁₋₁₀ alkoxy, C₆₋₁₂ aryl, C₁₋₆ halo substituted alkyl up to per halo alkyl, C_{6-C12} halo substituted aryl up to per halo aryl, C_{3-C12} halo substituted cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C_{3-C12} hetaryl up to per halo heteraryl, halo substituted C_{7-C24} aralkyl up to per halo aralkyl, halo substituted C_{7-C24} alkaryl up to per halo alkaryl, and -C(O)R_g ; or

-OSi(R_f)₃ where R_f is hydrogen, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, C_{3-C10} cycloalkyl having 0-3 heteroatoms selected from O, S and N, C₆₋₁₂ aryl, C_{3-C12} hetaryl

having 1-3 heteroatoms selected from O, S and N, C₇₋₂₄ aralkyl, substituted C₁₋₁₀ alkyl, substituted C₁₋₁₀ alkoxy, substituted C₃₋₁₂ cycloalkyl having 0-3 heteroatoms selected from O, S and N, substituted C₃₋₁₂ heteraryl having 1-3 heteroatoms selected from O, S, and N, substituted C₆₋₁₂ aryl, and substituted C₇₋₂₄ alkaryl, where R_f is a substituted group
 5 it is substituted halogen up to per halo, hydroxy, C₁₋₁₀ alkyl, C₃₋₁₂ cycloalkyl having 0-3 heteroatoms selected from O, S and N, C₃₋₁₂ heteraryl having 1-3 heteroatoms selected from N, S and O, C₁₋₁₀ alkoxy, C₆₋₁₂ aryl, C₇₋₂₄ alkaryl, C₇₋₂₄ aralkyl, C₁₋₆ halo substituted alkyl up to per halo alkyl, C₆₋₁₂ halo substituted aryl up to per halo aryl, C₃₋₁₂ halo substituted cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to
 10 per halo cycloalkyl, halo substituted C₃₋₁₂ heteraryl up to per halo heteraryl, halo substituted C₇₋₂₄ aralkyl up to per halo aralkyl, halo substituted C₇₋₂₄ alkaryl up to per halo alkaryl, and -C(O)R_g,

or

b) R_a and R_b together form a 5-7 member heterocyclic structure of 1-3
 15 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O with substituents selected from the group consisting of halogen up to per halo, hydroxy, C₁₋₁₀ alkyl, C₃₋₁₂ cycloalkyl having 0-3 heteroatoms selected from O, S and N, C₃₋₁₂ heteraryl having 1-3 heteroatoms selected from N, S and O, C₁₋₁₀ alkoxy, C₆₋₁₂ aryl, C₇₋₂₄ alkaryl, C₇₋₂₄ aralkyl, halo
 20 substituted C₁₋₆ alkyl up to per halo alkyl, halo substituted C₆₋₁₂ aryl up to per halo aryl, halo substituted C₃₋₁₂ cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C₃₋₁₂ heteraryl up to per halo heteraryl, halo substituted C₇₋₂₄ aralkyl up to per halo aralkyl, halo substituted C₇₋₂₄ alkaryl up to per halo alkaryl, and -C(O)R_g,

25

or

c) one of R_a or R_b is -C(O)-, a C₁₋₅ divalent alkylene group or a substituted C₁₋₅ divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members,

wherein the substituents of the substituted C_1 - C_5 divalent alkylene group are selected from the group consisting of halogen, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms selected from O, S and N, C_{3-12} hetaryl having 1-3 heteroatoms selected from N, S and O, C_{1-10} alkoxy, C_{6-12} aryl, C_7 - C_{24} alkaryl, C_7 - C_{24} aralkyl, C_{1-6} halo substituted alkyl up to per halo alkyl, C_6 - C_{12} halo substituted aryl up to per halo aryl, C_3 - C_{12} halo substituted cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C_3 - C_{12} hetaryl up to per halo heteraryl, halo substituted C_7 - C_{24} aralkyl up to per halo aralkyl, halo substituted C_7 - C_{24} alkaryl up to per halo alkaryl, and $-C(O)R_g$,

where R_g is C_{1-10} alkyl; $-CN$, $-CO_2R_d$, $-OR_d$, $-SR_d$, $-NO_2$, $-C(O)R_e$, $-NR_dR_e$, $-NR_dC(O)OR_e$ and $-NR_dC(O)R_e$, and R_d and R_e are independently selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{1-10} alkoxy, C_{3-10} cycloalkyl having 0-3 heteroatoms selected from O, N and S, C_{6-12} aryl, C_3 - C_{12} hetaryl with 1-3 heteroatoms selected from O, N and S and C_7 - C_{24} aralkyl, C_7 - C_{24} alkaryl, up to per halo substituted C_1 - C_{10} alkyl, up to per halo substituted C_3 - C_{10} cycloalkyl having 0-3 heteroatoms selected from O, N and S, up to per halo substituted C_6 - C_{14} aryl, up to per halo substituted C_3 - C_{12} hetaryl having 1-3 heteroatoms selected from O, N, and S, halo substituted C_7 - C_{24} alkaryl up to per halo alkaryl, and up to per halo substituted C_7 - C_{24} aralkyl,

20

W is independently selected from the group consisting of $-CN$, $-CO_2R^7$, $-C(O)NR^7R^7$, $-C(O)-R^7$, $-NO_2$, $-OR^7$, $-SR^7$, $-NR^7R^7$, $-NR^7C(O)OR^7$, $-NR^7C(O)R^7$, C_1 - C_{10} alkyl, C_1 - C_{10} alkoxy, C_2 - C_{10} alkenyl, C_1 - C_{10} alkenoyl, C_3 - C_{10} cycloalkyl having 0-3 heteroatoms selected from O, S and N, C_6 - C_{14} aryl, C_7 - C_{24} alkaryl, C_7 - C_{24} aralkyl, C_3 - C_{12} heteroaryl having 1-3 heteroatoms selected from O, N and S, C_4 - C_{23} alkheteroaryl having 1-3 heteroatoms selected from O, N and S, substituted C_1 - C_{10} alkyl, substituted C_1 - C_{10} alkoxy, substituted C_2 - C_{10} alkenyl, substituted C_1 - C_{10} alkenoyl, substituted C_3 - C_{10} cycloalkyl having 0-3 heteroatoms selected from O, N and S, substituted C_6 - C_{12} aryl, substituted C_3 - C_{12} hetaryl having 1-3 heteroatoms selected from O, N and S, substituted C_7 - C_{24} aralkyl, substituted C_7 - C_{24} alkaryl, substituted C_4 - C_{23} alkheteroaryl having 1-3 heteroatoms selected from O, N and S, and $-Q-Ar$;

30

R^7 is independently selected from H, C_1 - C_{10} alkyl, C_1 - C_{10} alkoxy, C_2 - C_{10} alkenyl, C_1 - C_{10} alkenoyl, C_3 - C_{10} cycloalkyl having 0-3 heteroatoms selected from O, S and N, C_6 - C_{14} aryl, C_3 - C_{13} hetaryl having 1-3 heteroatoms selected from O, N and S, C_7 - C_{14} alkaryl, C_7 - C_{24} aralkyl, C_4 - C_{23} alkheteroaryl having 1-3 heteroatoms selected from O, N and S, up to per-halosubstituted C_1 - C_{10} alkyl, up to per-halosubstituted C_3 - C_{10} cycloalkyl having 0-3 heteroatoms selected from O, N and S, up to per-halosubstituted C_6 - C_{14} aryl, up to per-halosubstituted C_3 - C_{13} hetaryl having 1-3 heteroatoms selected from O, N and S, up to per-halosubstituted C_7 - C_{24} aralkyl, up to per-halosubstituted C_7 - C_{24} alkaryl, and up to per-halosubstituted C_4 - C_{23} alkheteroaryl; and

each Z is independently selected from the group consisting of -CN, $-\text{CO}_2R^7$, $-\text{C}(\text{O})R^7$, $-\text{C}(\text{O})\text{NR}^7R^7$, $-\text{NO}_2$, $-\text{OR}^7$, $-\text{SR}^7$, $-\text{NR}^7R^7$, $-\text{NR}^7\text{C}(\text{O})\text{OR}^7$, $-\text{NR}^7\text{C}(\text{O})R^7$, C_1 - C_{10} alkyl, C_1 - C_{10} alkoxy, C_2 - C_{10} alkenyl, C_1 - C_{10} alkenoyl, C_3 - C_{10} cycloalkyl having 0-3 heteroatoms selected from O, N and S, C_6 - C_{14} aryl, C_3 - C_{13} hetaryl having 1-3 heteroatoms selected from O, N and S, C_7 - C_{24} alkaryl, C_7 - C_{24} aralkyl, C_4 - C_{23} alkheteroaryl having 1-3 heteroatoms selected from O, N and S, substituted C_1 - C_{10} alkyl, substituted C_1 - C_{10} alkoxy, substituted C_2 - C_{10} alkenyl, substituted C_1 - C_{10} alkenoyl, substituted C_3 - C_{10} cycloalkyl having 0-3 heteroatoms selected from O, N and S, substituted C_6 - C_{12} aryl, substituted C_7 - C_{24} alkaryl, substituted C_7 - C_{24} aralkyl and substituted C_4 - C_{23} alkheteroaryl having 1-3 heteroatoms selected from O, N and S; wherein if Z is a substituted group, the one or more substituents are selected from the group consisting of -CN, $-\text{CO}_2R^7$, $-\text{COR}^7$, $-\text{C}(\text{O})\text{NR}^7R^7$, $-\text{OR}^7$, $-\text{SR}^7$, $-\text{NO}_2$, $-\text{NR}^7R^7$, $-\text{NR}^7\text{C}(\text{O})R^7$, and $-\text{NR}^7\text{C}(\text{O})\text{OR}^7$.

25

3. A compound as in claim 1 wherein M is one or more bridging groups selected from the group consisting of $-\text{O}-$, $-\text{S}-$, $-\text{N}(\text{R}^7)-$, $-(\text{CH}_2)_m-$, $-\text{C}(\text{O})-$, $-\text{CH}(\text{OH})-$, $-(\text{CH}_2)_m\text{O}-$, $-(\text{CH}_2)_m\text{S}-$, $-(\text{CH}_2)_m\text{N}(\text{R}^7)-$, $-\text{O}(\text{CH}_2)_m-\text{CHX}^a-$, $-\text{CX}^a_2-$, $-\text{S}-(\text{CH}_2)_m-$ and $-\text{N}(\text{R}^7)(\text{CH}_2)_m-$, where $m=1-3$, X^a is halogen and R^7 is as defined in claim 1.

4. A compound as in claim 1 wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by -OH.

5. A compound as in claim 1 wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by a moiety having an ionizable hydrogen and a pKa of 10 or less.

6. A compound of claim 1 wherein B of Formula I is a substituted or unsubstituted six member aryl moiety or six member hetaryl moiety, said hetaryl moiety having 1 to 4 members selected from the group of hetaryl atoms consisting of nitrogen, oxygen and sulfur with the balance of the hetaryl moiety being carbon.

7. A compound of claim 1 wherein B of Formula I is an unsubstituted phenyl group, an unsubstituted pyridyl group, an unsubstituted pyrimidinyl, a phenyl group substituted by a substituent selected from the group consisting of halogen and W_n wherein W and n are as defined in claim 1, a pyrimidinyl group substituted by a substituent selected from the group constituting of halogen and W_n, whereas W and n are as defined in Claim 1, or a substituted pyridyl group substituted by a substituent selected from the group consisting of halogen and W_n wherein W and n are as defined in claim 1.

8. A compound of claim 6 wherein B of Formula I is a substituted phenyl group, a substituted pyrimidinyl group, or substituted pyridyl group substituted 1 to 3 times by 1 or more substituents selected from the group consisting of -CN, halogen, C₁-C₁₀ alkyl, C₁-C₁₀ alkoxy, -OH, up to per halo substituted C₁-C₁₀ alkyl, up to per halo substituted C₁-C₁₀ alkoxy or phenyl substituted by halogen up to per halo.

9. A compound of claim 1, wherein L, the six member cyclic structure bound directly to D, is a substituted or unsubstituted 6 member aryl moiety or a substituted or unsubstituted 6 member hetaryl moiety, wherein said hetaryl moiety has 1 to 4 members selected from the group of heteroatoms consisting of nitrogen, oxygen and sulfur with the balance of said hetaryl moiety being carbon, wherein the one or more substituents are selected from the group consisting of halogen and W_n wherein W and n are as defined in claim 1.

10. A compound of claim 8, wherein L, the 6 member cyclic structure bound directly to D, is a substituted phenyl, unsubstituted phenyl, substituted pyrimidinyl, unsubstituted pyrimidinyl, substituted pyridyl or unsubstituted pyridyl group.

11. A compound of claim 1, wherein said substituted cyclic moiety L¹ comprises a 5 to 6 membered aryl moiety or hetaryl moiety, wherein said heteraryl moiety comprises 1 to 4 members selected from the group of heteroatoms consisting of nitrogen, oxygen and sulfur.

12. A compound of claim 1, wherein said substituted cyclic moiety L¹ is phenyl, pyridinyl or pyrimidinyl.

13. A compound of claim 3, wherein said substituted cyclic moiety L¹ is phenyl, pyridinyl or pyrimidinyl.

14. A compound of claim 6, wherein said substituted cyclic moiety L¹ is phenyl, pyridinyl or pyrimidinyl.

15. A compound of claim 8, wherein said substituted cyclic moiety L¹ is phenyl, pyridinyl or pyrimidinyl.

16. A compound of claim 9, wherein said substituted cyclic moiety L¹ is phenyl, pyridinyl or pyrimidinyl.

17. A compound of claim 10, wherein said substituted cyclic moiety L¹ is phenyl, pyridinyl or pyrimidinyl.

18. A compound of claim 14, wherein M is one or more bridging groups selected from the group consisting of -O-, -S-, -N(R⁷)-, -(CH₂)_m-, -C(O)-, -CH(OH)-, -(CH₂)_mO-, -(CH₂)_mS-, -(CH₂)_mN(R⁷)-, -O(CH₂)_m-, -CHX^a-, -CX^a₂-, -S-(CH₂)_m- and -N(R⁷)(CH₂)_m-, where m= 1-3, X^a is halogen and R⁷ is hydrogen or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen up to per halo.

19. A compound of claim 15, wherein M is one or more bridging groups selected from the group consisting of -O-, -S-, -N(R⁷)-, -(CH₂)_m-, -C(O)-, -CH(OH)-, -(CH₂)_mO-, -(CH₂)_mS-, -(CH₂)_mN(R⁷)-, -O(CH₂)_m-, -CHX^a-, -CX^a₂-, -S-(CH₂)_m- and -N(R⁷)(CH₂)_m-, where m= 1-3, X^a is halogen and R⁷ is hydrogen or a carbon based moiety

of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen up to per halo.

20. A compound of claim 16, wherein M is one or more bridging groups selected from the group consisting of -O-, -S-, -N(R⁷)-, -(CH₂)_m-, -C(O)-, -CH(OH)-, -
5 (CH₂)_mO-, -(CH₂)_mS-, -(CH₂)_mN(R⁷)-, -O(CH₂)_m- CHX^a-, -CX^a₂-, -S-(CH₂)_m- and -
N(R⁷)(CH₂)_m-, where m= 1-3, X^a is halogen and R⁷ is hydrogen or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen up to per halo.

21. A compound of claim 17, wherein M is one or more bridging groups
10 selected from the group consisting of -O-, -S-, -N(R⁷)-, -(CH₂)_m-, -C(O)-, -CH(OH)-, -
(CH₂)_mO-, -(CH₂)_mS-, -(CH₂)_mN(R⁷)-, -O(CH₂)_m- CHX^a-, -CX^a₂-, -S-(CH₂)_m- and -
N(R⁷)(CH₂)_m-, where m= 1-3, X^a is halogen and R⁷ is hydrogen or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen up to per halo.

22. A compound of claim 1 wherein L¹ is additionally substituted 1 to 3 times
15 by one or more substituents selected from the group consisting of C₁-C₁₀ alkyl, up to per
halo substituted C₁-C₁₀ alkyl, -CN, -OH, halogen, C₁-C₁₀ alkoxy and up to per halo
substituted C₁-C₁₀ alkoxy.

23. A compound of claim 13 wherein L¹ is additionally substituted 1 to 3
20 times by one or more substituents selected from the group consisting of C₁-C₁₀ alkyl, up
to per halo substituted C₁-C₁₀ alkyl, -CN, -OH, halogen, C₁-C₁₀ alkoxy and up to per halo
substituted C₁-C₁₀ alkoxy.

24. A compound of claim 18 wherein L¹ is additionally substituted 1 to 3
times by one or more substituents selected from the group consisting of C₁-C₁₀ alkyl, up
25 to per halo substituted C₁-C₁₀ alkyl, -CN, -OH, halogen, C₁-C₁₀ alkoxy and up to per halo
substituted C₁-C₁₀ alkoxy.

25. A compound of claim 19 wherein L¹ is additionally substituted 1 to 3
times by one or more substituents selected from the group consisting of C₁-C₁₀ alkyl, up
to per halo substituted C₁-C₁₀ alkyl, -CN, -OH, halogen, C₁-C₁₀ alkoxy and up to per halo
30 substituted C₁-C₁₀ alkoxy.

26. A compound of claim 20 wherein L^1 is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C_1 - C_{10} alkyl, up to per halo substituted C_1 - C_{10} alkyl, -CN, -OH, halogen, C_1 - C_{10} alkoxy and up to per halo substituted C_1 - C_{10} alkoxy.

5 27. A compound of claim 21 wherein L^1 is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C_1 - C_{10} alkyl, up to per halo substituted C_1 - C_{10} alkyl, -CN, -OH, halogen, C_1 - C_{10} alkoxy and up to per halo substituted C_1 - C_{10} alkoxy.

28. A compound of claim 1 wherein L^1 is substituted by $-C(O)R_x$.

10 29. A compound of claim 1 wherein L^1 is substituted by $-SO_2R_x$.

30. A compound of claim 1 wherein L^1 is substituted only by $-C(O)R_x$.

31. A compound of claim 1 wherein L^1 is substituted only by $-SO_2R_x$.

32. A compound of claim 1 wherein L^1 is substituted by $-C(O)R_x$ or $-SO_2R_x$, wherein R_x is NR_aR_b .

15 33. A compound of claim 13 wherein L^1 is substituted by $-C(O)R_x$ or $-SO_2R_x$, wherein R_x is NR_aR_b , and R_a and R_b are

a) independently hydrogen,

a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen, or

20 $-OSi(R_f)_3$ where R_f is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or

25 b) R_a and R_b together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O substituted by halogen, hydroxy

or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or

- 5 c) one of R_a or R_b is $-C(O)-$, a C_1-C_5 divalent alkylene group or a substituted C_1-C_5 divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C_1-C_5 divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.

10 34. A compound of claim 18 wherein L^1 is substituted by $-C(O)R_x$ or $-SO_2R_x$, wherein R_x is NR_aR_b and R_a and R_b are independently hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.


15 35. A compound of claim 19 wherein L^1 is substituted by $-C(O)R_x$, wherein R_x is NR_aR_b and R_a and R_b are independently hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.

20 36. A compound of claim 20 wherein L^1 is substituted by $-C(O)R_x$ or $-SO_2R_x$, wherein R_x is NR_aR_b and R_a and R_b are independently hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.

25 37. A compound of claim 21 wherein L^1 is substituted by $-C(O)R_x$ or $-SO_2R_x$, wherein R_x is NR_aR_b and R_a and R_b are independently hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of

up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.

38. A compound of Formula I:



or a pharmaceutically acceptable salt thereof, wherein

D is $-NH-C(O)-NH-$,

10 A is a substituted moiety of up to 40 carbon atoms of the formula: $-L-(M-L^1)_q$, where L is a 6 membered aryl moiety or a 6 membered hetaryl moiety bound directly to D, L^1 comprises a substituted cyclic moiety having at least 5 members, M is a bridging group having at least one atom, q is an integer of from 1-3; and each cyclic structure of L and L^1 contains 0-4 members of the group consisting of nitrogen, oxygen and sulfur, and

15 B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur,

wherein L^1 is substituted by at least one substituent selected from the group consisting of $-SO_2R_x$, $-C(O)R_x$ and $-C(NR_y)R_z$,

20 R_y is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally halosubstituted, up to per halo,

25 R_z is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;

R_x is R_z or NR_aR_b where R_a and R_b are

a) independently hydrogen,

a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy

and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen, or

-OSi(R_f)₃ where R_f is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or

b) R_a and R_b together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O substituted by halogen, hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or

c) one of R_a or R_b is -C(O)-, a C₁-C₅ divalent alkylene group or a substituted C₁-C₅ divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C₁-C₅ divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;

where B is substituted, L is substituted or L¹ is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and W_n, where n is 0-3;

wherein each W is independently selected from the group consisting of -CN, -CO₂R⁷, -C(O)NR⁷R⁷, -C(O)-R⁷, -NO₂, -OR⁷, -SR⁷, -NR⁷R⁷, -NR⁷C(O)OR⁷, -NR⁷C(O)R⁷, -Q-Ar, and carbon based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents independently selected from the group consisting of -CN, -CO₂R⁷, -C(O)R⁷, -C(O)NR⁷R⁷, -OR⁷, -SR⁷, -NR⁷R⁷, -NO₂, -NR⁷C(O)R⁷, -NR⁷C(O)OR⁷ and halogen up to per-halo; with each R⁷ independently selected from H or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen,

10042203-01102

wherein Q is -O-, -S-, -N(R⁷)-, -(CH₂)_m-, -C(O)-, -CH(OH)-, -(CH₂)_mO-,
-(CH₂)_mS-, -(CH₂)_mN(R⁷)-, -O(CH₂)_m-CHX^a-, -CX^a₂-, -S-(CH₂)_m- and -N(R⁷)(CH₂)_m-,
where m= 1-3, and X^a is halogen;

Ar is a 5- or 6-member aromatic structure containing 0-2 members selected from
5 the group consisting of nitrogen, oxygen and sulfur, which is optionally substituted by
halogen, up to per-halo, and optionally substituted by Z_{n1}, wherein n1 is 0 to 3 and each Z
is independently selected from the group consisting of -CN, -CO₂R⁷, -C(O)R⁷,
-C(O)NR⁷R⁷, -NO₂, -OR⁷, -SR⁷, -NR⁷R⁷, -NR⁷C(O)OR⁷, -NR⁷C(O)R⁷, and a carbon
10 based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from
N, S and O and optionally substituted by one or more substituents are selected from the
group consisting of -CN, -CO₂R⁷, -COR⁷, -C(O)NR⁷R⁷, -OR⁷, -SR⁷, -NO₂, -NR⁷R⁷,
-NR⁷C(O)R⁷, and -NR⁷C(O)OR⁷, with R⁷ as defined above; and

wherein M is one or more bridging groups selected from the group consisting of -O-, -S-,
-N(R⁷)-, -(CH₂)_m-, -C(O)-, -CH(OH)-, -(CH₂)_mO-, -(CH₂)_mS-, -(CH₂)_mN(R⁷)-, -O(CH₂)_m-
15 CHX^a-, -CX^a₂-, -S-(CH₂)_m- and -N(R⁷)(CH₂)_m-, where m= 1-3, X^a is halogen.

39. A compound of Formula I:



20 or a pharmaceutically acceptable salt thereof, wherein

D is -NH-C(O)-NH-,

A is a substituted moiety of up to 40 carbon atoms of the formula: -L-(M-L¹)_q,
where L is a substituted or unsubstituted phenyl or peritonal moiety bound directly to D,
L¹ comprises a substituted phenyl, peritonal or pyrimidinyl moiety, M is a bridging
25 group having at least one atom, q is an integer of from 1-3; and

B is a substituted or unsubstituted phenyl or pyridine group bound directly to
D,

wherein L¹ is substituted by at least one substituent selected from the group
consisting of -SO₂R_x, -C(O)R_x and -C(NR_y)R_z,

2011042003-011400T

R_y is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally halosubstituted, up to per halo, and ;

R_z is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;

R_x is R_z or NR_aR_b where R_a and R_b are

- a) independently hydrogen,
 - 10 a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen, or
 - 15 $-OSi(R_f)_3$ where R_f is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or
- b) R_a and R_b together form a 5-7 member heterocyclic structure of 1-3
 - 20 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O substituted by halogen, hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or
- c) one of R_a or R_b is $-C(O)-$, a C_1-C_5 divalent alkylene group or a substituted
 - 25 C_1-C_5 divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C_1-C_5 divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;

where B is substituted, L is substituted or L¹ is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and W_n, where n is 0-3;

wherein each W is independently selected from the group consisting of -CN, -CO₂R⁷, -C(O)NR⁷R⁷, -C(O)-R⁷, -NO₂, -OR⁷, -SR⁷, -NR⁷R⁷, -NR⁷C(O)OR⁷, -NR⁷C(O)R⁷, -Q-Ar, and carbon based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents independently selected from the group consisting of -CN, -CO₂R⁷, -C(O)R⁷, -C(O)NR⁷R⁷, -OR⁷, -SR⁷, -NR⁷R⁷, -NO₂, -NR⁷C(O)R⁷, -NR⁷C(O)OR⁷ and halogen up to per-halo; with each R⁷ independently selected from H or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen,

wherein Q is -O-, -S-, -N(R⁷)-, -(CH₂)_m-, -C(O)-, -CH(OH)-, -(CH₂)_mO-, -(CH₂)_mS-, -(CH₂)_mN(R⁷)-, -O(CH₂)_m-CHX^a-, -CX^a₂-, -S-(CH₂)_m- and -N(R⁷)(CH₂)_m-, where m= 1-3, and X^a is halogen;

Ar is a 5- or 6-member aromatic structure containing 0-2 members selected from the group consisting of nitrogen, oxygen and sulfur, which is optionally substituted by halogen, up to per-halo, and optionally substituted by Z_{n1}, wherein n1 is 0 to 3 and each Z is independently selected from the group consisting of -CN, -CO₂R⁷, -C(O)R⁷, -C(O)NR⁷R⁷, -NO₂, -OR⁷, -SR⁷, -NR⁷R⁷, -NR⁷C(O)OR⁷, -NR⁷C(O)R⁷, and a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents selected from the group consisting of -CN, -CO₂R⁷, -COR⁷, -C(O)NR⁷R⁷, -OR⁷, -SR⁷, -NO₂, -NR⁷R⁷, -NR⁷C(O)R⁷, and -NR⁷C(O)OR⁷; and

wherein M is one or more bridging groups selected from the group consisting of -O-, -S-, -N(R⁷)-, -(CH₂)_m-, -C(O)-, -CH(OH)-, -(CH₂)_mO-, -(CH₂)_mS-, -(CH₂)_mN(R⁷)-, -O(CH₂)_m-CHX^a-, -CX^a₂-, -S-(CH₂)_m- and -N(R⁷)(CH₂)_m-, where m= 1-3, X^a is halogen.

40. A compound as in claim 38 wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by -OH.

41. A compound as in claim 38 wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by a moiety having an ionizable hydrogen and a pKa of 10 or less.

42. A compound as in claim 39 wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by -OH.

43. A compound as in claim 39 wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by a moiety having an ionizable hydrogen and a pKa of 10 or less.

44. A compound as in claim 38 wherein substituents for B and L and additional substituents for L^1 , are selected from the group consisting of C_1 - C_{10} alkyl up to per halo substituted C_1 - C_{10} alkyl, CN, OH, halogen, C_1 - C_{10} alkoxy and up to per halo substituted C_1 - C_{10} alkoxy.

45. A compound as in claim 39 wherein substituents for B and L and additional substituents for L^1 , are selected from the group consisting of C_1 - C_{10} alkyl up to per halo substituted C_1 - C_{10} alkyl, CN, OH, halogen, C_1 - C_{10} alkoxy and up to per halo substituted C_1 - C_{10} alkoxy.

46. A compound of claim 38 wherein L^1 is substituted by $C(O)R_x$ or SO_2R_x .

47. A compound of claim 39 wherein L^1 is substituted by $C(O)R_x$ or SO_2R_x .

48. A compound of claim 46 wherein R_x is NR_aR_b and R_a and R_b are independently hydrogen and a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen..

49. A compound of claim 47 wherein R_x is NR_aR_b and R_a and R_b are independently hydrogen and a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.

50. A compound of claim 1 which is a pharmaceutically acceptable salt of a compound of formula I selected from the group consisting of

A₂
a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and

10 b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.

51. A compound of claim 2 which is a pharmaceutically acceptable salt of a compound of formula I selected from the group consisting of

A₃ 15 a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and

b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.

25 52. A compound of claim 33 which is a pharmaceutically acceptable salt of a compound of formula I selected from the group consisting of

A₄ a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene

10042203-01102
sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and

- 5 b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.

53. A compound of claim 38 which is a pharmaceutically acceptable salt of a compound of formula I selected from the group consisting of

- 10 a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene
AS sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic
15 acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and

- b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.

20 54. A compound of claim 39 which is a pharmaceutically acceptable salt of a compound of formula I selected from the group consisting of

- a) basic salts of organic acids and inorganic acids selected from the group
A6 consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene
25 sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and

b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.

55. A pharmaceutical composition comprising a compound of claim 1 or a
5 pharmaceutically acceptable salt of a compound of formula I, and a physiologically acceptable carrier.

56. A pharmaceutical composition comprising a compound of claim 2
consistent with formula I or a pharmaceutically acceptable salt thereof, and a
physiologically acceptable carrier.

10 57. A pharmaceutical composition comprising a compound of claim 33
consistent with formula I or a pharmaceutically acceptable salt thereof, and a
physiologically acceptable carrier.

58. A pharmaceutical composition comprising a compound of claim 38
consistent with formula I or a pharmaceutically acceptable salt thereof, and a
15 physiologically acceptable carrier.

59. A pharmaceutical composition comprising a compound of claim 39
consistent with formula I or a pharmaceutically acceptable salt thereof and a
physiologically acceptable carrier.

60. A compound selected from the group consisting of
20 3-tert butyl phenyl ureas of Table 1 above;
5-tert butyl-2-methoxyphenyl ureas of Table 2 above;
5-(trifluoromethyl)-2 phenyl ureas of Table 3 above;
3-(trifluoromethyl) -4 chlorophenyl ureas of Table 4 above;
3-(trifluoromethyl)-4-bromophenyl ureas of Table 5 above;
25 5-(trifluoromethyl)-4-chloro-2 methoxyphenyl ureas of Table 6 above; and
ureas 101-103 in Table 7 above.

61. A compound selected from the group consisting of
- the 3-*tert*-butyl phenyl ureas:
- N*-(3-*tert*-butylphenyl)-*N'*-(4-(3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea and
N-(3-*tert*-butylphenyl)-*N'*-(4-(4-acetylphenoxy)phenyl) urea;
- 5 the 5-*tert*-butyl-2-methoxyphenyl ureas:
- N*-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(1,3-dioxoisindolin-5-yloxy)phenyl) urea,
N-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(1-oxoisindolin-5-yloxy)phenyl) urea,
N-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(4-methoxy-3-(*N*-
10 methylcarbamoyl)phenoxy)phenyl) urea and
N-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea;
- the 2-methoxy-5-(trifluoromethyl)phenyl ureas:
- N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-carbamoyl-4-pyridyloxy)phenyl)
15 urea,
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-
pyridyloxy)phenyl) urea,
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl)
urea,
20 *N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-
pyridyloxy)phenyl) urea,
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-
pyridylthio)phenyl) urea,
25 *N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(2-chloro-4-(2-(*N*-methylcarbamoyl)(4-
pyridyloxy))phenyl) urea and
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(3-chloro-4-(2-(*N*-methylcarbamoyl)(4-
pyridyloxy))phenyl) urea;
- the 4-chloro-3-(trifluoromethyl)phenyl ureas:
- 30 *N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-carbamoyl-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea and

5 *N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

the 4-bromo-3-(trifluoromethyl)phenyl ureas:

10 *N*-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridylthio)phenyl) urea,

15 *N*-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(2-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea and

N-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(3-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea; and

20 the 2-methoxy-4-chloro-5-(trifluoromethyl)phenyl ureas:

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

25 *N*-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(2-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea and

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea.

30 62. A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administering a compound of Formula I of claim 1.

201110-011101

63. A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administering a compound of Formula I of claim 33.

64. A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administering a compound of Formula I of claim 38.

5 65. A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administering a compound of Formula I of claim 39.

66. A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administering a compound selected from the group consisting of

3-tert butyl phenyl ureas of Table 1 above;

10 5-tert butyl-2-methoxyphenyl ureas of Table 2 above;

5-(trifluoromethyl)-2 phenyl ureas of Table 3 above;

3-(trifluoromethyl)-4 chlorophenyl ureas of Table 4 above;

3-(trifluoromethyl)-4-bromophenyl ureas of Table 5 above;

5-(trifluoromethyl)-4-chloro-2 methoxyphenyl ureas of Table 6 above; and

15 ureas 101-103 in Table 7 above.

67. A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administering a compound selected from the group consisting of the 3-tert butyl phenyl ureas:

N-(3-tert-butylphenyl)-*N'*-(4-(3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea and

20 *N*-(3-tert-butylphenyl)-*N'*-(4-(4-acetylphenoxy)phenyl) urea;

the 5-tert-butyl-2-methoxyphenyl ureas:

N-(5-tert-butyl-2-methoxyphenyl)-*N'*-(4-(1,3-dioxoisindolin-5-yloxy)phenyl) urea,

N-(5-tert-butyl-2-methoxyphenyl)-*N'*-(4-(1-oxoisindolin-5-yloxy)phenyl) urea,

25 *N*-(5-tert-butyl-2-methoxyphenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea and

N-(5-tert-butyl-2-methoxyphenyl)-*N'*-(4-(3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea;

the 2-methoxy-5-(trifluoromethyl)phenyl ureas:

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-carbamoyl-4-pyridyloxy)phenyl) urea,

5 *N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,

10 *N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridylthio)phenyl) urea,

15 *N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(2-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea and

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(3-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea;

the 4-chloro-3-(trifluoromethyl)phenyl ureas:

20 *N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-carbamoyl-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea and

25 *N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea;

the 4-bromo-3-(trifluoromethyl)phenyl ureas:

30 *N*-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

20442203-011102
N-(4-bromo-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(4-bromo-3-(trifluoromethyl)phenyl)-N'-(3-(2-(N-methylcarbamoyl)-4-pyridylthio)phenyl) urea,

5 N-(4-bromo-3-(trifluoromethyl)phenyl)-N'-(2-chloro-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))phenyl) urea and

N-(4-bromo-3-(trifluoromethyl)phenyl)-N'-(3-chloro-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))phenyl) urea; and

10 the 2-methoxy-4-chloro-5-(trifluoromethyl)phenyl ureas:

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-N'-(3-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

15 N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-N'-(2-chloro-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))phenyl) urea and

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-N'-(3-chloro-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))phenyl) urea.